Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
EGFL7 encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. Zusätzlich bieten wir Ihnen EGFL7 Kits (19) und EGFL7 Proteine (12) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 71 products:
Human Monoclonal EGFL7 Primary Antibody für ELISA, WB - ABIN565550
Fish, Santoro, Morton, Yu, Yeh, Wythe, Ivey, Bruneau, Stainier, Srivastava: miR-126 regulates angiogenic signaling and vascular integrity. in Developmental cell 2008
Human Monoclonal EGFL7 Primary Antibody für ELISA - ABIN565551
Badiwala, Tumiati, Joseph, Sheshgiri, Ross, Delgado, Rao: Epidermal growth factor-like domain 7 suppresses intercellular adhesion molecule 1 expression in response to hypoxia/reoxygenation injury in human coronary artery endothelial cells. in Circulation 2010
Human Polyclonal EGFL7 Primary Antibody für IF (cc), IF (p) - ABIN733988
Huang, Yuan, Wan, Liu, Chen, Zhan, Li: VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network. in International journal of clinical and experimental pathology 2014
Human Polyclonal EGFL7 Primary Antibody für ELISA, WB - ABIN4365051
Delfortrie, Pinte, Mattot, Samson, Villain, Caetano, Lauridant-Philippin, Baranzelli, Bonneterre, Trottein, Faveeuw, Soncin: Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. in Cancer research 2011
we demonstrate for the first time the mechanisms by which lumens are generated within the major vessels in Xenopus and implicate EGFL7 in modulating cell shape and cell-cell junctions to drive proper lumen morphogenesis.
CASZ1 (zeige CASZ1 Antikörper)/Egfl7/RhoA (zeige RHOA Antikörper) pathway is necessary for promoting endothelial cell behaviors associated with proper vascular assembly.
These data suggest that Egfl7 provides endothelial cells (EC) with a cue for their extension into the vascular area and in establishing EC cell polarity.
EGFL7 provides a proper microenvironment for endothelial cell migration, thereby enabling accurate patterning.
Egfl7 is crucial for placental vascularization and embryonic growth.
the angiogenic factor (zeige VEGFA Antikörper) Egfl7 activates the Flt3/Flt3 (zeige FLT3 Antikörper) ligand (zeige FLT3LG Antikörper) pathway and is a key molecular driver enforcing thymus progenitor generation and thereby directly links endothelial cell biology to the production of T cell-based adaptive immunity
EGFL7 is required for VEGF (zeige VEGFA Antikörper) upregulation of the Akt (zeige AKT1 Antikörper)/Erk (1 (zeige MAPK3 Antikörper)/2) pathway during angiogenesis.
EGFL7 enhances EGFR (zeige EGFR Antikörper)-AKT (zeige AKT1 Antikörper) signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.
Egfl7 could be a HIF-1alpha (zeige HIF1A Antikörper) responsive gene regulated by oxygen tension.
Using the BPH/5 model of pre-eclampsia (PE), we show that the downregulation of Egfl7 in compromised placentas occurs pr (zeige NOTCH1 Antikörper)ior to the onset of characteristic maternal signs of PE.
egfl7 is initially expressed in all endothelial cells and then is progressively restricted to veins and to their neighbouring capillaries.
EGFL7 is expressed in the bone microenvironment and has a role in promoting endothelial cell migration and tube-like structure formation through integrin-mediated pathways.
Expression of Egfl7 in breast and lung carcinoma cells accelerates tumor growth and metastasis in immunocompetent mice but not in immunodeficient mice.
Overexpression of endothelial Egfl7 is associated with impaired angiogenesis and altered Notch (zeige NOTCH1 Antikörper) signaling
In conclusion, miR (zeige MLXIP Antikörper)-126 could inhibit tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression
This phase II trial evaluated the efficacy of parsatuzumab (also known as MEGF0444A), a humanized anti-EGFL7 IgG1 monoclonal antibody, in combination with modified FOLFOX6 (mFOLFOX6) (folinic acid, 5-fluorouracil, and oxaliplatin) bevacizumab in patients with previously untreated metastatic colorectal cancer
Oncogenic activation of EGFRwt in GBM is likely maintained by a continuous EGFL7 autocrine flow line.
our results indicated epidermal growth factor-like domain multiple 7 protein participates in growth hormone-secreting pituitary adenoma proliferation and invasion regulation via Notch2/DLL3 signaling pathway. These findings raised the possibility that epidermal growth factor-like domain multiple 7 protein might serve as a useful biomarker to assess growth hormone-secreting pituitary adenoma invasion and prognosis
Egfl7 is thus an endogenous and constitutive repressor of blood vessel endothelial cell activation in normal and inflammatory conditions and participates in a loop of regulation of activation of these cells by pro-inflammatory cytokines.
Up-regulated MALAT1 promoted the invasion and metastasis of GC, and the increase of EGFL7 expression was a potential mechanism via altering its H3 histone (zeige HIST1H3B Antikörper) acetylation level
These findings suggest that the stimulating effect of EGFL7-ESCs (zeige NR2E3 Antikörper) on fibroblast proliferation and migration may provide a useful strategy for wound healing.
A gene expression study was conducted to investigate the levels of Egfl7 and miRNA126-5p in human carotid artery atherosclerotic plaques
By regulating endothelial cell adhesion, EGFL7 plays a key role in the regulation of glioma angiogenesis.
The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF (zeige VEGFA Antikörper), suggests a possible important role of this angiogenic factor (zeige VEGFA Antikörper) in a later oncogenic and infiltrative/metastatic phase.
This gene encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. The encoded protein may play a role in regulating vasculogenesis. This protein may be involved in the growth and proliferation of tumor cells. Alternate splicing results in multiple transcript variants.
EGF-like-domain, multiple 7
, epidermal growth factor-like protein 7
, EGF-like protein 7
, NEU1 protein
, NOTCH4-like protein
, multiple EGF-like domains protein 7
, multiple epidermal growth factor-like domains protein 7
, vascular endothelial statin
, vascular endothelial-statin
, EGF-like domain 7
, EGF-like domain-containing protein 7
, Estrogen-regulated protein CBL20 20.4kD
, Estrogen-regulated protein CBL20, 20.4kD
, multiple EGF-like domain protein 7
, multiple epidermal growth factor-like domain protein 7